SYS6043, a B7-H3/Top1 antibody-drug conjugate (ADC), began Phase 1 dose escalation in solid tumor malignancies, according to the study listing. The start of dose escalation highlights ongoing clinical emphasis on B7-H3 immune-escape biology and topoisomerase I payloads as developers pursue differentiated therapeutic windows in heterogeneous solid tumors.